Five-Year Disease Prevalence Only One Driver of R&D Investment
The five-year figure doesn't always determine which cancer types are most commonly being studied in late-phase trials.
Five-year disease prevalence is certainly a factor-but apparently not the only one-determining which cancer types are most commonly being studied in late-phase clinical trials. IMS Health's analysis of the distribution of Phase III trials reveals that, as would be expected, cancers with higher five-year disease prevalence are the subject of more late-phase trials. But there are exceptions (see Figure 1).
The first is lung cancer. It is the clear leader in terms of the volume of Phase III trials, yet has about the same five-year prevalence as cervical and stomach cancers, both of which are involved in dramatically fewer trials. This may be tied to the fact that the molecular targets in non-small cell lung cancer have been long-since identified and extensively studied. The second exception is ovarian cancer, which has one of the lowest five-year prevalence rates, but is being heavily studied in Phase III trials due to the fact that several genetic mutations can affect the outcome for ovarian cancer patients.
Thus, a low five-year disease prevalence does not always inhibit research investment, provided that the genetic target can be identified in patients. - IMS Health
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
